An interventional study of Inspiratory and Oropharyngeal Muscle Strengthening in Obstructive Sleep Apnea, sponsored by Centre Hospitalier Universitaire de Saint Etienne. Recruiting at 2 sites in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-18.
Sponsored by Centre Hospitalier Universitaire de Saint Etienne · Not applicable, Interventional, and Supportive care
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 201 studies in Sleep Apnea, Obstructive with a site in France — 39 open to participants now, 48 under way, 4 of them phase 3. Sleep Apnea, Obstructive · France.
Among the 201 studies in Sleep Apnea, Obstructive with a site in France, this one is the 82nd largest by planned enrollment of the 133 interventional ones that give a count, is one of 9 that started in 2024, is one of 105 with no phase, reaches primary completion later than 26 of the 47 other live ones, and was the 172nd registered.
2,245 studies on the registry are indexed under Sleep Apnea, Obstructive; 476 are open to participants now.
Browse Sleep Apnea, Obstructive studies →39 of the 201 studies in Sleep Apnea, Obstructive with a site in France are open now. Recruiting first, the newest first:
University Hospital, Grenoble · Sites in France
Ages 18–75
Hospices Civils de Lyon · Sites in France
Ages 4–17
University Hospital, Grenoble · Sites in France
Ages 18–85
Assistance Publique - Hôpitaux de Paris · Sites in France
Ages 18–84
Hospices Civils de Lyon · Sites in France
Ages 5 mo–6 mo
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 316 Sleep Apnea, Obstructive studies recruiting now, 149 (47%) set no upper age limit and 123 (39%) stop at 75 or younger; 52 take children under 18; 66 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
201 studies; the count open now beside each. This study's row is marked.
First in 2001; this study’s year is marked. 9 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 38 is below the median of 52 across 1,475 interventional studies indexed under Sleep Apnea, Obstructive.
Median enrollment 52 across the 133 interventional studies, 140 across the 67 observational. Of the 121 that completed or were terminated, 6 (5%) have results posted.
This tab as a report to print or save as PDF → With an account.
38 of 201 have an industry lead sponsor. The 10 most frequent:
Centre Hospitalier Universitaire de Saint Etienne is the lead sponsor of 598 studies on the registry; 128 are open to participants now.
Centre Hospitalier Universitaire de Saint Etienne has 9 studies filed under Sleep Apnea, Obstructive — fewer than ten, so there is no comparison to draw.
13 of the studies in Sleep Apnea, Obstructive with a site in France that are under way reach primary completion within a year, 2 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07225686Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea on Positive Airway Pressure Therapy | 2027-08-20 |
| NCT07226765Phase 3AmgenMaridebart Cafraglutide Versus Placebo in Adult Participants With Obstructive Sleep Apnea Not on Positive Airway Pressure (PAP) Therapy | 2027-08-30 |
| NCT07283289Centre Hospitalier Intercommunal de Toulon La Seyne sur MerPrevalence of Obstructive Sleep Apnea in Patients With Peripheral Arterial Occlusive Disease | 2026-11 |
| NCT05939934University Hospital, AngersImpact of the Mandibular Advancement Device on Sleep Apnea During CPAP Withdrawal | 2026-11 |
| NCT07792746Clinique du MillenaireSleep Apnea Biomarkers and Adherence to Continuous Positive Airway Pressure | 2026-12-31 |
Add all 13 to your calendar (.ics) → With an account.
Among the 201 studies in Sleep Apnea, Obstructive with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The Obstructive Sleep Apnea hypopnea Syndrome (OSAS), whose prevalence is 4% of the French population, can lead to serious health consequences (risk of road accidents, onset of cardiovascular disease, etc.). OSAS corresponds to a certain number of interruptions (apneas) or reductions (hypopneas) of ventilation during sleep. The weakening of the tone of the inspiratory and oropharyngeal muscles is one of the main causes of upper airways obstruction during the inspiratory phase.
For patients with moderate OSAS, with few or no symptoms, without associated cardiovascular comorbidities, there is no recommended treatment. Rehabilitate the inspiratory and oropharyngeal muscles through muscle strengthening seems to be an alternative to this problem. Therefore, this study proposes a complete rehabilitation care evaluating the effectiveness of the strengthening of inspiratory and oropharyngeal muscles in subject with moderate OSAS.
The criteria were revised on the registry on Sep 25, 2026. See what changed
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
for MRI
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Home training to strengthen Inspiratory and Oropharyngeal muscles
Other: Inspiratory and Oropharyngeal Muscle Strengthening
No intervention
Patients will conduct the training at home, 5 days a week for 3 months. They will perform 2 sets of 30 inspirations against resistance (POWERbreathe® K5 , Powerbreathe International Limited, UK), equal to 70% Maximum Inspiratory Pressure (MIP). Patients will be guided for oropharyngeal exercises. The sessions will be supervised by the investigator every 3 weeks. During sessions with the investigator, sessions recorded in the device will be downloaded to verify compliance. A MIP measurement will be performed to adjust the resistance of the device.
Apnea-Hypopnea Index (AHI)
AHI is measured by polygraphy or polysomnography. It is not a score
Time frame: At 3 months
Maximum inspiratory pressure measurement (cmH2O)
Measured by POWERbreathe® K5
Time frame: At 3 and 9 Months
Neck circumference (cm)
The neck circumference is measured by Magnetic Resonance Imagery (RMI)
Time frame: At 3 months
Epworth sleepiness score
Sleep quality assessment using the Epworth sleepiness score. From 0 to 24. If score up to 10 then the patient has signs of excessive daytime sleepiness
Time frame: At 3 and 9 Months
Pittsburgh Sleep quality index
Sleep quality assessment using the Pittsburgh Sleep quality index. From 0 to 21. Score 0 = very good sleep quality. Score 21 = very poor sleep quality
Time frame: At 3 and 9 Months
Quality of life scale : Short Form 12 (SF12)
Quality of life assessment using the scale SF12 From 43 to 118 the higher the score, the better the quality of life
Time frame: At 3 and 9 Months
PICOT fatigue scale
Fatigue assessment using the PICOT scale From 0 to 32 If score up to 22 then the patient has signs of excessive sleepiness
Time frame: At 3 and 9 Months
AHI (Apnea-Hypopnea Index)
AHI is measured by polygraphy or polysomnography It is not a score
Time frame: At 9 months
Plan to share: Yes — Deidentified individual participant data underlying the results reported in the manuscript
Supporting information: Study protocol, Statistical analysis plan, Informed consent form
Time frame: Beginning 6 months following publication and ending 5 years after publication
Access criteria: Data will be available upon reasonable request to the corresponding author for scientifically sound proposals
No publications or documents are linked to this record.
Started Dec 2024 (actual). Primary completion is estimated for Aug 2027, 31 months after the start.
Of 510 non-industry interventional studies with no phase under Sleep Apnea, Obstructive, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 53. This study's planned 31 months is close to that.
Counting every sponsor, half of 628 studies reached it within 27 months; a quarter within 12 and three quarters within 50.
Since we started tracking on Sep 25, 2026, the dates moved once, on Sep 25, 2026: primary completion Aug 2026 → Aug 2027 and completion Aug 2026 → Aug 2027.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Centre Hospitalier Universitaire de Saint Etienne →